AT247, a promising candidate in the pursuit for next generation insulins to improve glycemic control
Cambridge, UK, 16 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate.
The manuscript titled ‘Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double blind, Crossover Study in Men with Type 1 Diabetes’ is…
CAMBRIDGE, UK (Dec 15th, 2020) – Nuclera, the UK-based biotech company developing desktop gene and protein printing technologies, announces that it has been awarded a Knowledge Transfer Partnership (KTP) grant in support of its work with researchers at the University of Southampton.
The research programme at the University of Southampton (Electronics and Computer Science) is being supervised by Professor of Bioelectronics, Hywel Morgan MBE. Professor Morgan’s expertise in biosensors and lab-on-a-chip technologies is supporting Nuclera’s focus on the specific engineering steps required to…
Development of a rapid acting concentrated insulin for advanced delivery systems and enabling fewer injections for high dose diabetics
Cambridge, UK., 14 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives announces dosing of the first patient in a Phase I clinical trial for its second clinical stage product, an ultra-concentrated rapid acting insulin, AT278.
AT278 is a novel proprietary formulation of concentrated insulin (500U/mL) that is designed to maintain rapid-acting characteristics in a…
We have just published a "Quick guide to implementing a Health and Safety management system". The guide is featured in the London Biosciences Innovation Centre (LBIC) newsletter. Read on page 4 for tips about how to achieve this: https://bit.ly/3oqhipQ. We also providing clients with biosafety support. For health, safety and biosafety support contact Bishop Simon Ltd at info@bishopsimon.co.uk
• State-of-the-art site will enable rapid delivery of engineered cell lines
• Powering ready-to-use edited cell-line portfolio expansion
• Enable comprehensive customization for research, diagnostic and therapeutic development
Cambridge, UK, 8 December 2020 – Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the opening of a new 16,000 sq ft purpose-fitted facility in Fremont, CA, which will serve as a major new site for its specialist cell engineering team. This state-of-the-art facility will enable delivery of engineered cell lines to power…
Cambridge, UK, 27th November 2020 / Sciad Newswire / One Nucleus reveals the finalists of its annual BioNewsRound Award, recognising life science companies who have announced exciting developments for patients and the wider sector. The finalists will pitch in the lead up to Genesis 2020 during which the winner will be announced.
Companies and research organisations were nominated for their most important news stories from the last year. These were assessed based on their impact on the organisation, whether they demonstrated an exciting development in…
BioIVT is contributing to four healthcare organizations this year, focusing on cancer, liver diseases, Alzheimer’s disease, and global health equity
Westbury, NY – Dec. 1, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is making several charitable donations in December to honor its clients' commitment to medical research.
This year, BioIVT is recognizing four non-profit healthcare organizations that support exceptional research to eradicate diseases that affect millions of people. During December, BioIVT will…
Cambridge, United Kingdom – 1 December 2020 - Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, is pleased to announce the appointment of Dr. Muthu Meyyappan as Chief Commercial Officer (CCO), effective immediately. Muthu will lead all aspects of Congenica’s sales and marketing and will be based in Boston, MA. His appointment follows the company’s recent Series C funding round which will enable the acceleration of global market development and further expansion into new therapy areas.
Muthu has more…
Global executive search and interim management specialist, Horton International UK, is delighted to announce the appointment of Emma Whittle as Partner within its Global Healthcare arm.
Emma brings to the team over 20 years’ experience within search and talent acquisition, built across a range of industries and with significant emphasis on hiring for the life sciences sectors, including technology digitalisation, medical technology and diagnostics.
Commenting on her appointment, Emma said: “This is an incredibly important time to be supporting the life sciences arena. R&D activity has…
A biotech start-up, whose technology aims to tackle cornea
donor tissue shortages and speed up life-changing transplants worldwide, has moved into a specialist lab facility – The Biosphere on Newcastle Helix.
3D Bio-Tissues and their technology is the outcome of more than 20 years of pioneering research. They specialise in creating ‘bio-equivalent’ structural tissues. Their technology works by applying novel bio-inspired manufacturing processes to generate complex structures. The team’s goal is to create structured, functional, and scalable tissues for both clinical and industrial use.…